IVF/ART/Infertility

FRIDAY, NOVEMBER 22

08:30-10:00 AMH vs AFC…AND THE WINNER IS……?
Hall A
Capsule Are we still debating on the role of AMH in the diagnosis and treatment of infertility?
Chairpersons Scott Nelson, UK
Nick Macklon, UK
08:30-09:15 Debate: Is AMH a good predictor for success in IVF cycles?
Pro: Antonio La Marca, Italy
Con: Joop Laven, Netherlands
Discussion
09:15-10:00 Debate: Are we really misinforming young women on their reproductive potential by using AMH and AFC testing?
Yes: Edgardo Somigliana, Italy
No: Antonio La Marca, Italy
Discussion
10:00-10:20 COFFEE BREAK AND POSTER VIEWING
EXIBITION AREA
10:20-11:50 PCOS/PCO
Hall A
Capsule PCOS is considered the most common endocrine disorder in reproductive age. However, the prevalence (6.5-17.8%), as well as the long-term risks, vary widely with the diagnostic tests and criteria. Should we change the criteria?
Chairpersons Roger A. Lobo, USA
Zion Ben Rafael
, Israel
10:20-11:05 Debate: Androgens are the villain in PCOS
Con: Joop Laven, Netherlands
Pro: Jerome Strauss, USA
Discussion
11:05-11:50 Debate: We must screen PCOS cases for the presence of the metabolic syndrome
Pro: Bart Fauser, Netherlands
Con: Phillippe Bouchard, France
Discussion
11:50-12:10 BREAK
EXIBITION AREA
12:10-13:40 INDUSTRY SUPPORTED SESSION
Hall A
13:40-14:30 LUNCH BREAK AND POSTER VIEWING
EXIBITION AREA
14:30-16:30 STIMULATION, OOCYTES AND EMBRYOS
Hall A
Capsule Stimulation, the first step in IVF, has never had consensus..
Chairperson Scott Nelson, UK
14:30-15:00 Debate: Ovarian stimulation: More or Less?
Less is more: Geeta Nargund, UK
No! New twists in ovarian stimulation: More is better: Dominique de Ziegler, France
Discussion
15:00-15:20 GnRH agonists and IVF: The end …. or not?
Joelle Belaisch Allart, France
15:20-15:40 The numbers of small (2-5 and 6-9 mmm) follicles are inversely correlated in both normal women and in PCOS: What is the missing link?
Sophie Catteau-Jonard, France
15:40-16:30 COGI SPECIAL COUNTERCURRENT SYMPOSIA
Capsule The next stage in improving the result, is understanding what’s wrong with what we’re doing
15:40-16:05 RCTs may not be the answer to all outstanding questions in IVF
Bart Fauser, Netherlands
16:05-16:30 Repeated implantation failure:  An iatrogenic phenomenon which leads to two unnecessary activities
Zion Ben Rafael, Israel
16:30-16:50 COFFEE BREAK AND POSTER VIEWING
EXIBITION AREA
16:50-18:20 ADENOMYOSIS AND ENDOMETRIOSIS
Hall A
Capsule The concept that uterine adenomyosis and pelvic endometriosis as well as endometriotic lesions at distant sites of the body share a common pathophysiology with endometriosis was promoted almost a decade ago. What is the current thinking?
Chairpersons Marie-Madeline Dolmans, Belgium
Philippe Descamps, France
Aleksandar Stefanović, Serbia
16:50-17:10 Adenomyosis and deep endometriosis: Two linked diseases?
Jacques Donnez, Belgium
17:10-17:45 Debate: The endometrioma and the ovarian reserve: The challenge of the surgeon
To operate first: Herve Fernandez, France
ART before operation: Edgardo Somigliana, Italy
Discussion
17:45-18:20 Debate: Deep-endometriosis should be operated prior to ART
Pro for surgery first: Olivier Donnez, Belgium
Cons for IVF first (against surgery): Pietro Santulli, France
Discussion

SATURDAY, NOVEMBER 23

08:30-10:00 PGT-A
Hall A
Capsule Is PGS useful or harmful?
Chairpersons Simon Fishel, UK
Gerald Schatten, USA
08:30-09:00 PGT-A for Advances maternal age and repeated abortions, useful or harmful?
Nathan Treff, USA
09:00-09:30 RCT of PGT for aneuploidy by microarray of polar body in advance maternal age. Any advantage? The Esteem Study
Luca Ginaroli, Italy
09:30-10:00 PGD/PGT-A without embryo biopsy, is this the answer?
Samir Hamamah, France
10:00-10:20 COFFEE BREAK AND POSTER VIEWING
EXIBITION AREA
10:20-11:50 INDUTRY SUPPORTED SESSION
Hall A
11:50-12:10 BREAK
EXIBITION AREA
12:10-13:40 QUESTIONS AND ANSWERS
Hall A
Chairpersons Zion Ben Rafael¸ Israel
Rene Frydman, France
Bart Fauser, Netherlands
Discussants Edgardo Somigliana, Italy
Nick Macklon, UK
Joop Laven, Netherlands
Samir Hamamah, France
Simon Fishel, UK
Laura Rienzi¸ Italy
  • In which selected patient populations is PGS/ PGT-A proven beneficial
  • Freeze all embryos strategies in IVF for all
  • Duo stim? Why bother?
  • Embryo selection with highest implantation potential: Tell me how?
  • ERA test: Who can benefit
  • Natural and natural/mild cycles, are they the same? Are we misleading each other?
  • Is Machine Learning beginning to improve IVF outcomes; what can we expect in the  future
  • What is the best measure of IVF outcome from clinical, patients, healthcare system?
  • Is SET possible for all? lf not, what is the percentage of SET should we strive for? Should it be age dependent?
  • LH or hCG: Which is more important for ovarian stimulation?
13:40-14:30 LUNCH BREAK AND POSTER VIEWING
EXIBITION AREA
14:30-16:30 HITECH IVF:  ARTIFICIAL GAMETE AND EMBRYOS
Hall A
Capsule Current capability promise more ethical questions.
Chairpersons Dominique De Ziegler, France
Nick Macklon, UK
14:30-14:55 Artificial ovary
Marie Madeleine Dolmans, Belgium
14:55-15:15 Conception versus manufacturing:  ART Prospects with artificial gametes and assembled embryos
Gerald Schatten, USA
15:15-15:40 Self-organization of the human embryo in the absence of maternal tissues
Matteo Mole, UK
15:40-16:00 Expanding PGT to polygenic risk
Nathan Treff, USA
16:00-16:30 Special countercurrent lecture:
Are we overusing IVF
Fulco van der Veen, Netherlands
16:30-16:50 COFFEE BREAK AND POSTER VIEWING
EXIBITION AREA
16:50-18:20 FREEZE ALL
Hall A
Capsule Now that RCTs have failed to prove its usefulness, it’s time to discuss the overall advantages and disadvantages
Chairpersons Elena Labarta, Spain
Rene Frydman, France
16:50-17:20 Debate: Freeze only strategy for all?
Con: Ben Mol, Australia
Pro: Anja Pinborg, Denmark
Discussion
17:20-18:00 Debate: Should we measure progesterone on the day of a frozen embryo transfer?
No : Annalisa Racca, Belgium
Yes: Elena Labarta, Spain
Discussion
18:00-18:20 Comparing fresh and frozen embryo transfers in IVF; Cost effectiveness analysis
Ben Mol, Australia

FRIDAY, NOVEMBER 22

08:30-10:00 SCREENING OF THE MAN FOR INFERTILITY
Hall B
Capsule Have we neglected the treatment of male infertility? Can better screening improve the overall results?
Chairpersons Christopher Barratt,UK
Christopher De Jonge, USA
Giuseppe Tritto, France
08:30-08:35 Introduction
Christopher Barratt, UK
08:35-09:00 Screening of the man for infertility; Why its necessary (canary in the coal mine)
Michael Eisenberg, USA
09:00-09:25 The Male Reproductive Health initiative
Christopher De Jonge, USA
09:25-09:50 Use of Social Media platforms to inform the public about male reproductive health issues
Allan Pacey, UK
09:50-10:00 Discussion
10:00-10:20 COFFEE BREAK AND POSTER VIEWING
EXIBITION AREA
10:20-11:50 ADD-ON TREATMENTS
Hall B
Capsule Add-on treatments: The best solution to keep patients from quitting the program?
Chairpersons Anja Pinborg, Denmark
Ben MolAustralia
10:20-11:05 Debate: Standard IVF vs Add-on IVF – What if the patient is willing to pay for add-ons?
Con: Joyce Harper, UK
Pro: Simon Fishel, UK
Discussion
11:05-11:30 ICSI does not increase the cumulative live birth rate in non-male factor infertility
Elizabeth A. Sullivan, Australia
11:30-11:50 Is there a relationship between the time to ICSI and the reproductive outcomes?
Amelia Rodríguez-Aranda, Spain
11:50-12:10 BREAK
EXIBITION AREA
12:10-13:40 LABORATORY WORK
Hall B
Capsule Basic issues in Lab work are still controversial
Chairperson Mina Popovic, Belgium
12:10-12:30 IVF and the lab: Which culture medium to use
Aafke van Montfoort, Netherlands
12:30-13:15 Debate: Still room for embryo morphological evaluation?
Yes: in favor Luca Ginaroli, Italy
No: against Marine Poulain, France
Discussion
13:15-13:40 The secret lives of human embryos exposed through time-lapse.  An analysis of over 300 SET cycles
Diana Stein, Israel
13:40-14:30 LUNCH BREAK AND POSTER VIEWING
EXIBITION AREA
14:30-16:30 IMPLANTATION MODELS
Hall B
Capsule IVF failure is mainly due to embryonal or endometrial reasons?
Chairpersons Nick Macklon,UK
Simon Fishel, UK
14:30-14:50 Complex endometrial organoids to model embryo implantation
Emma Lucas, UK
14:50-15:15 Organoids from healthy and diseased endometrium as innovative research tools in reproductive biology
Hugo Vankelecom, Belgium
15:15-15:40 Implantation Clinic: Hope or hype?
Nick Macklon, UK
15:40-16:30 SPECIAL COGI COUNTERCURRENT LECTURES
15:40-16:05 Can IVF influence human evolution?
Hans Ivar Hanevik, Norway
16:05-16:30 Endometrial receptivity testing: Can the most reliable test stand up?
Samuel Dos Santos Ribeiro, Belgium
16:30-16:50 COFFEE BREAK AND POSTER VIEWING
EXIBITION AREA
16:50-18:20 BLASTOCYSTS
Hall B
Capsule Single euploid, morphologically intact blastocyst seems like the holy grail of IVF. So why we are still debating?
Chairpersons Laura Rienzi, Italy
Scott Nelson, UK
16:50-17:15 Chromosomal mosaicism in human blastocysts: The ultimate challenge of preimplantation genetic testing?
Mina PopovicBelgium
17:15-17:35 Prevalence of XXY karyotypes in human blastocysts: Multicenter data from 7549 trophectoderm biopsies obtained during preimplantation genetic testing cycles in IVF
Laura RienziItaly
17:35-18:20 Debate: Blastocyst-stage embryo transfer for all
Yes: Samir Hamamah, France
No: Amelia Rodríguez-Aranda, Spain
Discussion

SATURDAY, NOVEMBER 23

08:30-10:00 FERTILITY PRESERVATION
Hall B
Capsule With so many methods of fertility preservation, do they all offer similar probabilities?
Chairpersons Jacques Donnez, Belgium
Michael Grynberg, France
08:30-08:50 How many eggs do we need for preserving fertility?
Nathalie Sermondade, France
08:50-09:15 Oocytes or ovarian cortex cryopreservation for fertility preservation
Jean-Philippe Wolf, France
09:15-09:35 The place of IVM for fertility preservation
Michael Grynberg, France
09:35-10:00 Ovarian tissue cryopreservation and transplantation: Still experimental?
Marie-Madeline Dolmans, Belgium
10:00-10:20 COFFEE BREAK AND POSTER VIEWING
EXIBITION AREA
10:20-12:00 DIAGNOSIS OF INFERTILITY
Hall B
Capsule Why Should we keep doing HSG? Uterine transplantation, what kind of results can be expected?
Chairperson Rene Frydman, France
Katarina Jeremic, Serbia
10:20-10:40 Uterine transplantation – The French experience
Jean Marc Ayoubi, France
10:40-11:00 Failure in IVF. What’s next? A multidisciplinary approach
Rene Frydman, France
11:00-11:40 Debate: Hysterosalpingogram how?
Traditional oil-based HSG exploiting its therapeutic advantage: Ben Mol, Australia
Ecosy is a good alternative: Marc Even, France
Discussion
11:40-12:00 Management of low response
Scott Nelson, UK
12:00-12:10 BREAK
EXIBITION AREA
12:10-13:40 GO TO HALL A – QUESTIONS AND ANSWERS SESSION
Hall B
13:40-14:30 LUNCH BREAK AND POSTER VIEWING
EXIBITION AREA
14:30-16:30 WHAT’S NEW IN POI RESEARCH – I
Hall B
Capsule Can POI patients have any chance for fertility?
Chairpersons Lisa Webber, UK
Nicholas Panay, UK
14:30-14:50 Genetics of menopause
Joop Laven, Netherlands
14:50-15:20 Genetics of POI. Novel links with DNA repair/cancer genes
Micheline Misrahi, France
15:20-15:40 Fertility and management of Turner syndrome
Sophie Christin-Maitre, France
15:40-16:00 Stem cells in and out the ovaries: Promises for POI
Gabriel Livera, France
16:00-16:30 Special countercurrent lecture
Vaginal Lactobacilli: key to successful human reproduction and future antibiotic resistant therapy
Gary Ventolini, USA
16:30-16:50 COFFEE BREAK AND POSTER VIEWING
EXIBITION AREA
16:50-18:20 WHAT’S NEW IN POI RESEARCH – PART II
Hall B
Capsule Can POI patients have any chance for fertility?
Chairpersons Roger A. Lobo, USA
Micheline Misrahi, France
16:50-17:10 Can we reliably predict POI using AMH?
Bart Fauser, Netherlands
17:10-17:35 Regulation of physiological reproductive lifespan and female fertility
Grant Montgomery, Australia
17:35-17:55 Developing new guidelines from a POI registry
Nicholas Panay, UK
17:55-18:20 The long-term health risks of POI
Lisa Webber, UK